<DrugInformationSummary id="CDR0000800541"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about tazemetostat hydrobromide
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.
  </DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/tazemetostathydrobromide">Tazemetostat Hydrobromide</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000751383">tazemetostat hydrobromide</TerminologyLink><GlossaryLink ref="CDR0000793179">tazemetostat hydrobromide</GlossaryLink><USBrandNames><USBrandName>Tazverik</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>TA-zeh-MEH-toh-stat HY-droh-BROH-mide</TermPronunciation><MediaLink ref="CDR0000795219" type="audio/mpeg" alt="" language="en" id="_5"/><MediaLink ref="CDR0000795218" type="audio/mpeg" alt="" language="es" id="_6"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7db07b5f-4e22-467c-9c0a-f830b08dbb1d&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Tazemetostat Hydrobromide</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7db07b5f-4e22-467c-9c0a-f830b08dbb1d&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_6"><Title>Use in Cancer</Title>                                                              
  <Para id="_7">Tazemetostat hydrobromide
         is approved to treat:</Para>                          
  <ItemizedList Style="bullet" id="_8">
   <ListItem><Strong><GlossaryTermRef href="CDR0000782481" dictionary="Cancer.gov" audience="Patient">Epithelioid sarcoma</GlossaryTermRef></Strong> that is <GlossaryTermRef href="CDR0000045955" dictionary="Cancer.gov" audience="Patient">locally advanced</GlossaryTermRef> or has <GlossaryTermRef href="CDR0000046283" dictionary="Cancer.gov" audience="Patient">metastasized</GlossaryTermRef> (spread to other parts of the body).  It is used in adults and in children aged 16 years and older whose disease cannot be removed by <GlossaryTermRef href="CDR0000045570" dictionary="Cancer.gov" audience="Patient">surgery</GlossaryTermRef>.¹</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000428287" dictionary="Cancer.gov" audience="Patient">Follicular lymphoma</GlossaryTermRef></Strong> that has <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapsed</GlossaryTermRef> (come back) or is <GlossaryTermRef href="CDR0000045863" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> (does not respond to treatment).  It is used in adults:<ItemizedList Style="bullet" id="_10"><ListItem>Whose <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumors</GlossaryTermRef> have a certain <GlossaryTermRef href="CDR0000046063" dictionary="Cancer.gov" audience="Patient">mutation</GlossaryTermRef> in the <GeneName><GlossaryTermRef href="CDR0000801889" dictionary="Cancer.gov" audience="Patient">EZH2</GlossaryTermRef></GeneName> <GlossaryTermRef href="CDR0000045693" dictionary="Cancer.gov" audience="Patient">gene</GlossaryTermRef> and who have received at least two  <GlossaryTermRef href="CDR0000045922" dictionary="Cancer.gov" audience="Patient">systemic therapies</GlossaryTermRef>.¹ </ListItem><ListItem> Who are not able to receive other therapies.¹</ListItem></ItemizedList> </ListItem>
   </ItemizedList>
  <Para id="_5">¹This use is approved under FDA’s <ExternalRef xref="https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm">Accelerated Approval Program</ExternalRef>. As a condition of approval, <GlossaryTermRef href="CDR0000799146" dictionary="Cancer.gov" audience="Patient">confirmatory trial(s)</GlossaryTermRef> must show that tazemetostat hydrobromide provides a clinical benefit in these patients.</Para><Para id="_9">Tazemetostat hydrobromide
         is also being studied in the treatment of other types of
         <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>.</Para>
 </Section><Section id="_About"><Title>More About Tazemetostat Hydrobromide</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/751383">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.17">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a620018.html">Tazemetostat Hydrobromide</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.18"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.19">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Cancer Therapies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C166954">Find Clinical Trials for Tazemetostat Hydrobromide</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2020-03-12</DateFirstPublished><DateLastModified>2020-11-02</DateLastModified></DrugInformationSummary>
